Literature DB >> 22457643

Progress in the diagnosis and treatment of inflammatory bowel disease.

Edward V Loftus1.   

Abstract

Entities:  

Year:  2011        PMID： 22457643      PMCID： PMC3061012     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  38 in total

1.  The effects of infliximab maintenance therapy on health-related quality of life.

Authors:  Brian G Feagan; Songkai Yan; Mohan Bala; Weihang Bao; Gary R Lichtenstein
Journal:  Am J Gastroenterol       Date:  2003-10       Impact factor: 10.864

2.  Current directions of biologic therapies in inflammatory bowel disease.

Authors:  Catherine Reenaers; Edouard Louis; Jacques Belaiche
Journal:  Therap Adv Gastroenterol       Date:  2010-03       Impact factor: 4.409

3.  Natalizumab for the treatment of Crohn's disease.

Authors:  Stephen J Bickston; Kishor Muniyappa
Journal:  Expert Rev Clin Immunol       Date:  2010-07       Impact factor: 4.473

4.  Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine.

Authors:  A Kandiel; A G Fraser; B I Korelitz; C Brensinger; J D Lewis
Journal:  Gut       Date:  2005-08       Impact factor: 23.059

5.  Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.

Authors:  Jean-Frédéric Colombel; William J Sandborn; Paul Rutgeerts; Robert Enns; Stephen B Hanauer; Remo Panaccione; Stefan Schreiber; Dan Byczkowski; Ju Li; Jeffrey D Kent; Paul F Pollack
Journal:  Gastroenterology       Date:  2006-11-29       Impact factor: 22.682

6.  CARD15 in inflammatory bowel disease and Crohn's disease phenotypes: an association study and pooled analysis.

Authors:  L E Oostenbrug; I M Nolte; E Oosterom; G van der Steege; G J te Meerman; H M van Dullemen; J P H Drenth; D J de Jong; K van der Linde; P L M Jansen; J H Kleibeuker
Journal:  Dig Liver Dis       Date:  2006-08-21       Impact factor: 4.088

7.  Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors:  Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

8.  Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID).

Authors:  J Y Mary; R Modigliani
Journal:  Gut       Date:  1989-07       Impact factor: 23.059

9.  Smoking and immunomodulators do not influence the response or duration of response to infliximab in Crohn's disease.

Authors:  David S Fefferman; Parag J Lodhavia; Mazen Alsahli; Kenneth R Falchuk; Mark A Peppercorn; Samir A Shah; Richard J Farrell
Journal:  Inflamm Bowel Dis       Date:  2004-07       Impact factor: 5.325

10.  Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.

Authors:  Stephen B Hanauer; William J Sandborn; Paul Rutgeerts; Richard N Fedorak; Milan Lukas; Donald MacIntosh; Remo Panaccione; Douglas Wolf; Paul Pollack
Journal:  Gastroenterology       Date:  2006-02       Impact factor: 22.682
View more
  6 in total

1.  Effect of Anti-TNF Agents on Postoperative Outcomes in Inflammatory Bowel Disease Patients: a Single Institution Experience.

Authors:  Chaya Shwaartz; Adam C Fields; Maximiliano Sobrero; Brian D Cohen; Celia M Divino
Journal:  J Gastrointest Surg       Date:  2016-07-12       Impact factor: 3.452

2.  Mortality Risk of Inflammatory Bowel Disease: A Case-Control Study of New York State Death Records.

Authors:  Angelica Nocerino; Alexandra Feathers; Elena Ivanina; Laura Durbin; Arun Swaminath
Journal:  Dig Dis Sci       Date:  2019-01-02       Impact factor: 3.199

3.  Thiopurine-methyltransferase variants in inflammatory bowel disease: prevalence and toxicity in Brazilian patients.

Authors:  Ana Teresa P Carvalho; Barbara C Esberard; Renata S B Fróes; Davy C M Rapozo; Ana B Grinman; Tatiana A Simão; Juliana C V C Santos; Antonio José V Carneiro; Luis Felipe Ribeiro-Pinto; Heitor S P de Souza
Journal:  World J Gastroenterol       Date:  2014-03-28       Impact factor: 5.742

4.  Dietary vitamin B6 intake modulates colonic inflammation in the IL10-/- model of inflammatory bowel disease.

Authors:  Jacob Selhub; Alexander Byun; Zhenhua Liu; Joel B Mason; Roderick T Bronson; Jimmy W Crott
Journal:  J Nutr Biochem       Date:  2013-10-02       Impact factor: 6.048

Review 5.  Medical Management of Crohn's Disease.

Authors:  Ajay K Gade; Nathan T Douthit; Erin Townsley
Journal:  Cureus       Date:  2020-05-29

6.  A single nucleotide polymorphism in dopamine beta hydroxylase (rs6271(C>T)) is over-represented in inflammatory bowel disease patients and reduces circulating enzyme.

Authors:  Eugene Gonzalez-Lopez; Yuka Kawasawa-Imamura; Lijun Zhang; Xuemei Huang; Walter A Koltun; Matthew D Coates; Kent E Vrana
Journal:  PLoS One       Date:  2019-02-28       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.